Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs iShares MSCI Taiwan ETF (EWT) Price & Performance

Abbott LaboratoriesTrade
iShares MSCI Taiwan ETFTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs iShares MSCI Taiwan ETF — how do they compare? Abbott Laboratories trades at $109.35 (market cap $187.95B), while iShares MSCI Taiwan ETF trades at $105.6. The key difference: Abbott Laboratories pays a 2.32% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.

ABTEWT
Market Cap
$187.95B
Sector
HealthBroad Market / Factor
52-Week High
$136.62$111.53
52-Week Low
$82.57$58.05
Enterprise Value
$214.96B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

iShares MSCI Taiwan ETF

EWT, the iShares MSCI Taiwan ETF, trades at $103.09, up 1.09% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights Taiwan's market outperformance, fueled by AI-driven semiconductor demand, with the ETF gaining over 60% year-to-date. Key support lies at $102, while resistance is at $104. The RSI_6 at 96.58 indicates overbought conditions, suggesting potential near-term consolidation.

The outlook remains positive due to Taiwan's critical role in the global semiconductor supply chain, though risks include geopolitical tensions with China and dependency on AI sector momentum. Analysts are bullish given the ETF's exposure to top performers like TSMC, but investors should monitor any shifts in foreign capital flows and semiconductor cycle dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT